Excellent therapeutic results achieved in chronic myeloid leukemia patients with front-line imatinib and early treatment modifications in suboptimal responders: A retrospective study on 91 unselected patients-Reference-Cited by-同舟云学术

Excellent therapeutic results achieved in chronic myeloid leukemia patients with front-line imatinib and early treatment modifications in suboptimal responders: A retrospective study on 91 unselected patients

Published:2013-07-23 Issue:10 Volume:88 Page:838-842
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol.

Author:

Cerrano Marco¹,Crisà Elena¹,Pregno Patrizia²,Aguzzi Chiara¹,Riccomagno Paola²,Boccadoro Mario¹,Ferrero Dario¹

Affiliation:

1. Hematology Division; Università degli Studi di Torino; Turin Italy

2. Hematology Division; Azienda Ospedaliera Città della Salute e della Scienza; Turin Italy

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajh.23501/fullpdf

Reference50 articles.

1. Evolution of therapies for chronic myelogenous leukemia;Santos;Cancer J,2011

2. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: A single-institution historical experience;Kantarjian;Blood,2012

3. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia;Kantarjian;N Engl J Med,2002

4. Survival benefit with imatinib mesylate versus interferon-α-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia;Kantarjian;Blood,2006

5. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia;Druker;N Engl J Med,2006

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The prevalence of hepatic and thyroid toxicity associated with imatinib treatment of chronic myeloid leukaemia: a systematic review;International Journal of Clinical Pharmacy;2023-12-26

2. Does switching to a second-generation tyrosine kinase inhibitor or increasing imatinib dose have long-term benefits in chronic myeloid leukemia patients with suboptimal responses under upfront standard-dose of imatinib?;Leukemia Research;2018-11

3. Early switch in tyrosine kinase inhibitor therapy for patients with chronic myeloid leukemia: An emerging clinical question;Critical Reviews in Oncology/Hematology;2016-07

4. Can prognostic scoring systems for chronic myeloid leukemia as established in adults be applied to pediatric patients?;Annals of Hematology;2015-04-19

5. How I treat newly diagnosed chronic myeloid leukemia in 2015;American Journal of Hematology;2014-11-24